1. Introduction: Peptides as Hypothesised Tissue Regulators
The school associated with Vladimir Khavinson, developed over several decades at the St. Petersburg Institute of Bioregulation and Gerontology (founded in 1992), proposes that short peptides of two to four amino acids act as tissue-specific regulators: each peptide is preferentially taken up by a particular organ or tissue, where it normalises gene expression and protein synthesis. On this account, aging involves a decline in the body’s production of such regulatory peptides, and their administration could restore normal function. The concept is elegant and the preparations have been used in Russian geriatric practice for decades. This article examines what has been demonstrated, what remains a hypothesis, and where the evidence is weak or contested.
The central caution is that two chemically distinct categories are often marketed under one name. The clinical literature largely concerns undefined polypeptide extracts (Thymalin, Epithalamin), while the products most widely sold to consumers are defined synthetic short peptides (Epitalon, Vilon and others) that are derivatives of those extracts and have far less human evidence behind them. The human mortality figures come from the extracts, not from the synthetics.
2. The Preparations: Extracts and Synthetic Peptides
- Thymalin. A polypeptide complex extracted from calf thymus, proposed to regulate T-cell maturation and cellular immunity — a rationale that overlaps with modern thymic-rejuvenation research. Administered intramuscularly in courses.
- Epithalamin. A polypeptide extract of bovine pineal gland, reported to restore melatonin rhythms and reproductive and neuroendocrine function in aged animals. It is the preparation on which the principal human mortality follow-up was conducted.
- Epitalon (Epithalon). A synthetic tetrapeptide, alanine-glutamate-aspartate-glycine (AEDG), designed from Epithalamin and produced by solid-phase synthesis. Because its sequence and mass are defined, it can be verified analytically — unlike the extracts, which have no reference sequence and cannot be authenticated by standard methods.
- Other agents. Later generations include Cortexin, Retinalamin, Prostatilen, and synthetic di- and tripeptides (for example, Vilon [Lys-Glu]) designed for defined composition and, in some cases, oral administration.
This distinction is not academic. An undefined animal-tissue extract and a synthetic tetrapeptide are different substances with different pharmacokinetics, impurity profiles, and risk considerations. Evidence for one does not transfer to the other, and much consumer marketing blurs the line.
3. The Proposed Mechanism and the «Peptide Theory of Aging»
Khavinson’s group has reported that tissue-derived peptide preparations stimulate the growth of explants specifically from the corresponding organ, that they alter the expression of numerous genes, and that they normalise endocrine and immune parameters in aged animals. From these observations the group proposed a «peptide theory of aging»: that aging is an evolutionarily determined process of changing gene expression, resulting in impaired synthesis of regulatory and tissue-specific peptides, which then provokes structural and functional decline; correcting the deficit by administering peptides could, in principle, normalise function.
The claim of tissue specificity is the theory’s most distinctive and most demanding element. A 2-4 amino-acid peptide has no obvious structural information for selective organ targeting, and the mechanisms proposed — uptake into target cells and regulation of transcription — have not been independently characterised at the molecular level. The changes in gene expression that have been reported are broad and nonspecific in pattern, which is difficult to reconcile with a strongly tissue-selective mechanism. At present, the peptide theory of aging is a hypothesis, and the tissue-specific action remains unproven outside the originating group.
4. The Telomerase Claim
The most widely publicised mechanistic claim concerns telomerase. In 2003 Khavinson and colleagues reported that Epitalon induced telomerase activity and elongated telomeres in human somatic cells that normally lack the enzyme (Bulletin of Experimental Biology and Medicine, 2003). If correct, this would be a striking finding: activation of telomerase is the canonical mechanism by which cells escape replicative senescence, and telomere maintenance is central to the biology recognised by the 2009 Nobel Prize.
Two qualifications are essential. First, for nearly two decades this finding rested on a single originating group with a commercial interest in the peptides. Second and more fundamentally, telomerase activation is a double-edged mechanism: the enzyme is also a near-universal feature that allows cancer cells to divide indefinitely. The telomere-maintenance target is therefore intrinsically entangled with oncogenic risk, a point that regulators have explicitly raised (Section 8). A claim to lengthen telomeres is not automatically a claim to healthy aging.
5. Animal Evidence
The strongest evidence for the peptide preparations is in animals. Anisimov, Mylnikov, and Khavinson reported in 1998 that Epithalamin increased mean lifespan by 11-31% across fruit flies, mice, and rats, with reduced mortality rate in several of the models. A later review by Anisimov and Khavinson (2009) described long-term treatment with some peptide preparations as increasing mean lifespan in rodents by 20-40%, slowing age-related biomarkers, and suppressing spontaneous and carcinogen-induced tumorigenesis. These are legitimate, multi-species results published in peer-reviewed journals.
Nevertheless, three limitations reduce their force. First, Khavinson was a co-author on essentially all of these studies, so they are not independent corroboration of his own claims. Second, the effects are not uniformly large: in at least one mouse strain the effect was much weaker or absent, attributed by the authors to dosage. Third, rodent lifespan experiments are highly sensitive to husbandry, pathogen load, and genetic background, and effects under one set of conditions may not generalise. The animal data establish that the question is worth testing; they do not establish that the peptides slow human aging.
6. Human Evidence: One Cohort, Many Caveats
The human evidence base for peptide bioregulators rests overwhelmingly on a single clinical follow-up reported by Khavinson and Morozov in 2003. In that study, 266 elderly and older people were given Thymalin and/or Epithalamin for the first two to three years of observation and followed for six to eight years. The reported results were a 2.0-2.4-fold decrease in acute respiratory illness, fewer clinical manifestations of ischaemic heart disease, hypertension, and osteoporosis, and, most prominently, reduced mortality: approximately 2.0-2.1-fold with Thymalin, 1.6-1.8-fold with Epithalamin, 2.5-fold with the combination, and 4.1-fold in a subgroup treated annually for six years.
These figures are striking, and they are also uninterpretable as evidence of efficacy. The publication is indexed as a randomised controlled trial, but the described methods do not include randomisation, blinding, or a specified placebo control; denominators and event counts per treatment arm are not published; and the effect sizes are unusually large for a mortality intervention. A mortality reduction of more than fourfold without a denominator cannot be assessed statistically. The study is the sole human basis for the longevity claim, and it has not been independently replicated. By any systematic-review standard, the human evidence is very weak, and the longevity claim should be regarded as unproven.
7. Independent Replication and the Cancer Question
The first substantial independent test of the mechanistic claim appeared in 2025. A group at Brunel University of London, unaffiliated with Khavinson and declaring no competing interests, reported in Biogerontology that Epitalon produced dose-dependent telomere lengthening in normal human epithelial and fibroblast cell lines, associated with upregulation of hTERT messenger RNA and increased telomerase enzyme activity. This is meaningful: it independently confirms, in vitro, the long-unreplicated finding that Epitalon can act on telomere maintenance.
The same study also found that Epitalon lengthened telomeres in two breast-cancer cell lines, not through telomerase but through alternative lengthening of telomeres (ALT) activation — a recombination-based mechanism. The normal cell lines showed little or no ALT activation. The authors interpreted this as reassuring for normal tissue, but the result simultaneously substantiates the theoretical concern that the same compound can promote telomere maintenance in malignant cells. The study was conducted in two-dimensional cell culture, a limitation the authors acknowledged; it provides no evidence about telomere length, mortality, or safety in living humans. A correction to the paper was subsequently published.
The net position after independent replication is thus: the telomerase/telomere mechanism is real in vitro; its translation to organisms, and any effect on aging or lifespan, remains untested.
8. Regulatory Status
Peptide bioregulators are registered as medicines in Russia for specific indications but are not approved in the European Union or by the U.S. Food and Drug Administration. The most recent regulatory scrutiny concerns Epitalon. At its meeting on 23-24 July 2026, the FDA’s Pharmacy Compounding Advisory Committee considered whether Epitalon-related bulk drug substances should be placed on the Section 503A Bulks List, which governs substances compounding pharmacies may use. FDA reviewers proposed against listing, finding the substance «not well characterised,» lacking critical data on impurities, aggregates, and bacterial endotoxins, lacking human safety data, and citing as a concern that «Epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer.» The advisory committee voted to recommend inclusion, but its votes are non-binding and final authorisation requires a formal rulemaking decision; as of late 2026 Epitalon remains non-approved, and any clinical use should be regarded as experimental.
9. Assessment and the Tests That Would Settle It
- Established. Epitalon can lengthen telomeres and increase telomerase activity in cultured human cells, now replicated by an independent group. Peptide preparations extend lifespan in several animal models under some conditions (originating group).
- Emerging / contested. Tissue-specific regulation of gene expression; the molecular basis of the proposed mechanism; safety of telomerase activation given the cancer association.
- Unproven. Reduced human mortality and slowed biological aging. The sole supporting cohort lacks randomisation, blinding, and denominators and has not been independently replicated.
- What would settle it. Independent replication of the telomerase finding in vivo; a pre-registered, randomised, placebo-controlled trial with a validated aging or mortality endpoint; and long-term monitoring for cancer and immunological effects. Half a century of clinical use is a reason to run such tests, not a substitute for them.
10. Conclusion
The Khavinson program deserves neither dismissal nor devotion, but the decisive experiment. Its animal data and now-independently-replicated in-vitro mechanism make the underlying hypothesis genuinely interesting; its human longevity data are, by modern standards, too weak to support the claim; and its principal mechanism carries a plausible oncogenic risk that has drawn formal regulatory concern. Until a pre-registered randomised trial demonstrates slowed biological aging or extended survival, peptide bioregulators contribute zero proven years of human life. A real institute, real registrations, and real animal results sit behind the category — but so does the fact that the human life-extension claim rests on one small, unreplicated cohort, and that what is sold to consumers is not always the substance the data were collected on.
Sources and Key Research Centers
- Khavinson VKh. «Peptides and ageing.» Neuroendocrinology Letters, 2002; 23(Suppl 3): 11-144. PMID: 12374906
- Khavinson VKh, Morozov VG. «Peptides of pineal gland and thymus prolong human life.» Neuroendocrinology Letters, 2003; 24(3-4): 233-240. PMID: 14523363
- Anisimov VN, Mylnikov SV, Khavinson VKh. «Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats.» Mechanisms of Ageing and Development, 1998; 103(2): 123-132. DOI: 10.1016/s0047-6374(98)00034-7
- Anisimov VN, Khavinson VKh. «Peptide bioregulation of aging: results and prospects.» Biogerontology, 2010; 11(2): 139-149. DOI: 10.1007/s10522-009-9249-8
- Khavinson V, Bondarev I, Butyugov A. «Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells.» Bulletin of Experimental Biology and Medicine, 2003; 135(6): 590-592. PMID: 12937682
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. «Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.» Biogerontology, 2025; 26(5): 178. DOI: 10.1007/s10522-025-10315-x (Correction: Biogerontology, 2025; 27(1): 1. DOI: 10.1007/s10522-025-10326-8)
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee. Briefing document on Epitalon-related bulk drug substances, 24 July 2026. FDA meeting materials
- Jaskelioff M, Muller FL, Paik JH, et al. «Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice.» Nature, 2011; 469(7328): 102-106. DOI: 10.1038/nature09603
- St. Petersburg Institute of Bioregulation and Gerontology — originating institution for Thymalin, Epithalamin, and Epitalon research.
- ClinicalTrials.gov — registry search for peptides in older adults (terms: thymalin, epitalon, thymus peptide elderly).